1405 related articles for article (PubMed ID: 11294039)
21. Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.
Nabeshima T; Mouri A; Murai R; Noda Y
Ann N Y Acad Sci; 2006 Nov; 1086():160-8. PubMed ID: 17185514
[TBL] [Abstract][Full Text] [Related]
22. Significance of dysfunctional glutamatergic transmission for the development of psychotic symptoms.
Pietraszek M
Pol J Pharmacol; 2003; 55(2):133-54. PubMed ID: 12926541
[TBL] [Abstract][Full Text] [Related]
23. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
Anand A; Charney DS; Oren DA; Berman RM; Hu XS; Cappiello A; Krystal JH
Arch Gen Psychiatry; 2000 Mar; 57(3):270-6. PubMed ID: 10711913
[TBL] [Abstract][Full Text] [Related]
24. Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers.
Gouzoulis-Mayfrank E; Heekeren K; Neukirch A; Stoll M; Stock C; Obradovic M; Kovar KA
Pharmacopsychiatry; 2005 Nov; 38(6):301-11. PubMed ID: 16342002
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway.
Kamiyama H; Matsumoto M; Otani S; Kimura SI; Shimamura KI; Ishikawa S; Yanagawa Y; Togashi H
Neuroscience; 2011 Mar; 177():159-69. PubMed ID: 21163337
[TBL] [Abstract][Full Text] [Related]
26. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions.
Tamminga CA; Holcomb HH; Gao XM; Lahti AC
Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():29-37. PubMed ID: 8866763
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of NMDA receptor models of schizophrenia: divergences in the behavioral effects of sub-chronic PCP and MK-801.
Seillier A; Giuffrida A
Behav Brain Res; 2009 Dec; 204(2):410-5. PubMed ID: 19716985
[TBL] [Abstract][Full Text] [Related]
28. Does ketamine mimic aspects of schizophrenic speech?
Covington MA; Riedel WJ; Brown C; He C; Morris E; Weinstein S; Semple J; Brown J
J Psychopharmacol; 2007 May; 21(3):338-46. PubMed ID: 17591660
[TBL] [Abstract][Full Text] [Related]
29. [Hypofrontality and negative symptoms in schizophrenia: synthesis of anatomic and neuropsychological knowledge and ecological perspectives].
Semkovska M; Bédard MA; Stip E
Encephale; 2001; 27(5):405-15. PubMed ID: 11760690
[TBL] [Abstract][Full Text] [Related]
30. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
Jentsch JD; Roth RH
Neuropsychopharmacology; 1999 Mar; 20(3):201-25. PubMed ID: 10063482
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.
Laruelle M; Frankle WG; Narendran R; Kegeles LS; Abi-Dargham A
Clin Ther; 2005; 27 Suppl A():S16-24. PubMed ID: 16198197
[TBL] [Abstract][Full Text] [Related]
32. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia.
Greene R
Hippocampus; 2001; 11(5):569-77. PubMed ID: 11732709
[TBL] [Abstract][Full Text] [Related]
33. Systemic administration of MK-801 produces an abnormally persistent latent inhibition which is reversed by clozapine but not haloperidol.
Gaisler-Salomon I; Weiner I
Psychopharmacology (Berl); 2003 Apr; 166(4):333-42. PubMed ID: 12599023
[TBL] [Abstract][Full Text] [Related]
34. Phencyclidine animal models of schizophrenia: approaches from abnormality of glutamatergic neurotransmission and neurodevelopment.
Mouri A; Noda Y; Enomoto T; Nabeshima T
Neurochem Int; 2007; 51(2-4):173-84. PubMed ID: 17669558
[TBL] [Abstract][Full Text] [Related]
35. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
Neill JC; Barnes S; Cook S; Grayson B; Idris NF; McLean SL; Snigdha S; Rajagopal L; Harte MK
Pharmacol Ther; 2010 Dec; 128(3):419-32. PubMed ID: 20705091
[TBL] [Abstract][Full Text] [Related]
36. Nicotine and smoker status moderate brain electric and mood activation induced by ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist.
Knott V; McIntosh J; Millar A; Fisher D; Villeneuve C; Ilivitsky V; Horn E
Pharmacol Biochem Behav; 2006 Sep; 85(1):228-42. PubMed ID: 17023037
[TBL] [Abstract][Full Text] [Related]
37. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats.
Homayoun H; Jackson ME; Moghaddam B
J Neurophysiol; 2005 Apr; 93(4):1989-2001. PubMed ID: 15590730
[TBL] [Abstract][Full Text] [Related]
38. [Frontal dementia or dementia praecox? A case report of a psychotic disorder with a severe decline].
Vanderzeypen F; Bier JC; Genevrois C; Mendlewicz J; Lotstra F
Encephale; 2003; 29(2):172-80. PubMed ID: 14567169
[TBL] [Abstract][Full Text] [Related]
39. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.
Yang CR; Svensson KA
Pharmacol Ther; 2008 Dec; 120(3):317-32. PubMed ID: 18805436
[TBL] [Abstract][Full Text] [Related]
40. [Neuropsychopharmacological study on an animal model for negative symptom of schizophrenia induced by repeated phencyclidine treatment].
Noda Y; Nabeshima T
Yakugaku Zasshi; 2000 Aug; 120(8):677-82. PubMed ID: 10946617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
